- Home
- XRTX vs APVO Comparison
XRTX vs APVO Comparison
Compare XRTX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- APVO
- Stock Information
- Founded
- XRTX 2011
- APVO 2016
- Country
- XRTX Canada
- APVO United States
- Employees
- XRTX N/A
- APVO N/A
- Industry
- XRTX Pharmaceuticals and Biotechnology
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- XRTX Health Care
- APVO Health Care
- Exchange
- XRTX Nasdaq
- APVO Nasdaq
- Market Cap
- XRTX 3.4M
- APVO 4.1M
- IPO Year
- XRTX N/A
- APVO N/A
- Fundamental
- Price
- XRTX $0.87
- APVO $2.96
- Analyst Decision
- XRTX
- APVO Strong Buy
- Analyst Count
- XRTX 0
- APVO 1
- Target Price
- XRTX N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- XRTX 211.8K
- APVO 6.7M
- Earning Date
- XRTX 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- XRTX N/A
- APVO N/A
- EPS Growth
- XRTX N/A
- APVO N/A
- EPS
- XRTX N/A
- APVO N/A
- Revenue
- XRTX N/A
- APVO N/A
- Revenue This Year
- XRTX N/A
- APVO N/A
- Revenue Next Year
- XRTX N/A
- APVO N/A
- P/E Ratio
- XRTX N/A
- APVO N/A
- Revenue Growth
- XRTX N/A
- APVO N/A
- 52 Week Low
- XRTX $0.80
- APVO $2.81
- 52 Week High
- XRTX $2.98
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- XRTX 49.13
- APVO 33.90
- Support Level
- XRTX $0.89
- APVO $2.92
- Resistance Level
- XRTX $1.03
- APVO $3.19
- Average True Range (ATR)
- XRTX 0.06
- APVO 1.05
- MACD
- XRTX 0.01
- APVO 0.24
- Stochastic Oscillator
- XRTX 42.98
- APVO 2.23
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.